Romania Pharma and Healthcare Sector Report 2020/2021

Healthcare expenditure in Romania has been increasing steadily in recent years (up by 15.6% y/y in 2017), but remains the lowest in the EU28, both in per capita purchasing power and as a share of GDP (5.2% in 2017). An Ageing population and under-development of primary and preventive care have been consistently straining the financing of the public healthcare system. The state remains the major source of funding of healthcare spending (78.7% of the total in 2017), but out-of-pocket payments are on the rise (20.5% share). While most of private spending is on pharmaceuticals, the poor state of public healthcare coupled with improving incomes has boosted demand for private healthcare services. In the pharmaceutical production sector, government policies aimed at alleviating the healthcare deficit have resulted in stagnating profits.

This report provides a complete and detailed analysis of the healthcare and pharmaceutical sector for [country name] . EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the healthcare and pharmaceutical sector in [country name]
• Access forecasts for growth in the sector
• View key data on healthcare spending and health insurance in [country name]
• Crystallise the forces both driving and restraining this sector in [country name]
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in [country name]
• Build a clear picture of trends and issues for sub-sectors (medical institutions, pharmaceuticals manufacturing and distribution channels).

See below for a complete table of report contents: